Keywords: isis, selects, antisense, drug, development, pharmaceuticals, usa

Isis selects antisense drug for development

Article | 27 September 2004

Print This

Isis Pharmaceuticals of the USA has selected ISIS 345794 for development, based on the findings from preclinical evaluation. The agent is ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in